These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19118074)

  • 21. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer.
    Glaessgen A; Jonmarker S; Lindberg A; Nilsson B; Lewensohn R; Ekman P; Valdman A; Egevad L
    APMIS; 2008 Oct; 116(10):888-95. PubMed ID: 19132982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How bad are positive margins after radical prostatectomy and how are they best managed?
    Nielsen ME
    J Urol; 2009 Oct; 182(4):1257-8. PubMed ID: 19683276
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: Guzzo TJ, Vira MA, Neway W, et al: Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology 69: 1147-1151, 2007.
    Guzzo TJ; Vira MA; Dey W; Hwang WT; Tomaszewski J; VanArsdalen K; Wein AJ; Malkowicz B
    Urology; 2008 Jun; 71(6):1230-1. PubMed ID: 18400267
    [No Abstract]   [Full Text] [Related]  

  • 24. Pelvic mass after prostatectomy. Pseudosarcomatous fibromyxoid tumor.
    Grigorian A; Ponsford Tipps AM; Derweesh IH; Boles SG; Sicklick JK
    JAMA Surg; 2014 Jul; 149(7):741-2. PubMed ID: 24871499
    [No Abstract]   [Full Text] [Related]  

  • 25. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Life expectancy estimation by nomogram.
    Froehner M
    J Clin Oncol; 2008 Feb; 26(4):690; author reply 691-3. PubMed ID: 18235138
    [No Abstract]   [Full Text] [Related]  

  • 27. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy.
    Fujita K; Nakayama M; Nakai Y; Takayama H; Nishimura K; Ujike T; Nishimura K; Aozasa K; Okuyama A; Nonomura N
    Cancer Sci; 2009 Jun; 100(6):1047-50. PubMed ID: 19385972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Radiotherapy for high-risk patients after radical prostatectomy for prostate cancer: immediate postoperative or salvage?].
    Pasquier D; Kouto H; Ballereau C
    Prog Urol; 2009 Jul; 19(7):447-56. PubMed ID: 19559374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognosis and predictive factors in prostate cancer].
    Albiges-Sauvin L; Lévy A; Massard C; Fizazi K
    Bull Cancer; 2009 Apr; 96(4):439-49. PubMed ID: 19357018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymph node assessment and lymphadenectomy in prostate cancer.
    Ordon M; Nam RK
    J Surg Oncol; 2009 Mar; 99(4):215-24. PubMed ID: 19170044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nomograms are more meaningful than severity-adjusted institutional comparisons for reporting outcomes.
    Hixson ED; Kattan MW
    Eur Urol; 2006 Apr; 49(4):600-3. PubMed ID: 16439054
    [No Abstract]   [Full Text] [Related]  

  • 34. Atypical ductal adenocarcinoma of the prostate with endometrioid immunohistological features.
    Lucan M; Vasiliu V; Iacob G; Lucan V
    Chirurgia (Bucur); 2009; 104(3):355-8. PubMed ID: 19601472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.
    Sakata T; Ferdous G; Tsuruta T; Satoh T; Baba S; Muto T; Ueno A; Kanai Y; Endou H; Okayasu I
    Pathol Int; 2009 Jan; 59(1):7-18. PubMed ID: 19121087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective.
    Capitanio U; Briganti A; Shariat SF; Karakiewicz PI
    Eur Urol; 2008 Oct; 54(4):717-9. PubMed ID: 18703272
    [No Abstract]   [Full Text] [Related]  

  • 37. Sequential testing approach as an efficient and easier alternative for the validation of new predictive technologies in the clinic.
    Beam CA; Gao W; Macias V; Liang W; Kajdacsy Balla A
    J Clin Oncol; 2009 Mar; 27(7):1087-90. PubMed ID: 19139434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do we need more nomograms for predicting outcomes in patients with prostate cancer?
    Kattan MW
    Nat Clin Pract Urol; 2008 Jul; 5(7):366-7. PubMed ID: 18506152
    [No Abstract]   [Full Text] [Related]  

  • 39. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.